All articles by Phillip Broadwith – Page 8
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
-
-
BusinessFormer Valeant and Philidor executives arrested for fraud
Prosecutors allege the men masterminded a kickback scheme between Valeant and the speciality pharmacy
-
BusinessOCP to invest $3.7bn in Ethiopian fertiliser plant
Output from joint venture between Ethiopian government and Moroccan state phosphate group will exceed domestic demand
-
OpinionUncertainty around Trump presidency is harmful to industry
Uncertainty is anathema to industry. Trump and Brexit are frustrations, but the wheels do not stop.
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
-
NewsExplainer: Are ‘flushable’ wet wipes really flushable?
Water companies are calling for all wipes to be classified as unflushable until an international standard is agreed
-
BusinessThird fatality confirmed in BASF incident
Crackers and related plants will restart over coming days
-
BusinessExplosion at BASF kills at least two
Six workers injured and a further two missing in Ludwigshafen, Germany
-
BusinessChemical activity on demand
Aqdot controls the release of encapsulated cargoes using supramolecular chemistry
-
OpinionBooster shot
Zika and Ebola have highlighted the pharmaceutical industry’s ability to respond to critical needs
-
BusinessIneos lands first US shale gas in UK
Massive tankers create a ‘virtual pipeline’ bringing feedstock to replace dwindling domestic supplies
-
BusinessJ&J to buy Abbott Medical Optics
Deal adds laser surgery and cataract lens replacements to J&J’s eyecare business
-
BusinessDanaher boosts diagnostics with Cepheid buyout
$4bn deal strengthens Danaher’s life sciences portfolio
-
-
BusinessJoined-up thinking
The rift between contract medicinal chemistry and chemical development needs to be bridged
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes